Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose–response study and open-label extension study

被引：0
|
作者：
Takashi Wada
Masaya Inagaki
Toru Yoshinari
Ryuji Terata
Naoko Totsuka
Miki Gotou
Gaia Hashimoto
机构：
[1] Kanazawa University,Department of Nephrology and Laboratory Medicine
[2] Mitsubishi Tanabe Pharma Corporation,Data Science Department, Ikuyaku. Integrated Value Development Division
[3] Mitsubishi Tanabe Pharma Corporation,Clinical Research and Development II Department, Ikuyaku. Integrated Value Development Division
来源：
Clinical and Experimental Nephrology | 2021年 / 25卷
关键词：
Diabetic nephropathy; Diabetic kidney disease; Dose-finding study; Fibrosis; Mineralocorticoid receptor antagonists; Apararenone;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：120 / 130
页数：10
相关论文
共 50 条
  • [1] Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose-response study and open-label extension study
    Wada, Takashi
    Inagaki, Masaya
    Yoshinari, Toru
    Terata, Ryuji
    Totsuka, Naoko
    Gotou, Miki
    Hashimoto, Gaia
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2021, 25 (02) : 120 - 130
  • [2] Belumosudil in diffuse cutaneous systemic sclerosis: a randomized, double-blind, open-label extension, placebo-controlled, phase 2 study
    Chung, Lorinda
    Silver, Richard M.
    Steen, Virginia
    Furst, Daniel E.
    Castelino, Flavia, V
    Trojanowski, Marcin
    Spiera, Robert
    Domsic, Robyn
    Rodriguez-Pla, Alicia
    Katsumoto, Tamiko R.
    Goulaouic, Helene
    Wang, Hong
    Espinasse, Melanie
    El-Chemaly, Souheil
    Wang, Rui
    RHEUMATOLOGY, 2025,
  • [3] Topiramate in migraine prophylaxis: An open-label extension of a double-blind, placebo-controlled study
    Hart, DE
    Calder, CS
    Storey, JR
    Riback, P
    Potter, DL
    Wymer, JP
    Beesley, BA
    NEUROLOGY, 2002, 58 (07) : A496 - A497
  • [4] Alefacept with methotrexate for treatment of psoriatic arthritis: Open-label extension of a randomized, double-blind, placebo-controlled study
    Mease, Philip J.
    Reich, Kristian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2009, 60 (03) : 402 - 411
  • [5] Results of the Open-Label Extension of a Phase 2, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of AMG 334 for the Prevention of Episodic Migraine
    Sun, Hong
    Dodick, David W.
    Goadsby, Peter
    Silberstein, Stephen
    Reuters, Uwe
    Ashina, Messoud
    Saper, Joel R.
    Cady, Roger
    Zhang, Feng
    Trotman, Marie-Louise
    Dietrich, Julie
    Lenz, Robert
    HEADACHE, 2015, 55 : 256 - 257
  • [6] Growth hormone deficiency and replacement therapy in Japan: Results of placebo-controlled double-blind study and open-label extension study
    Shimatsu, A.
    Tai, S.
    Kato, Y.
    Kohno, H.
    Tanaka, T.
    Teramoto, A.
    Chihara, K.
    DECADE OF HYPOCCS: THE CHANGING FACE OF PITUITARY DISEASE, 2008, 10 : 171 - +
  • [7] Add-on mirtazapine improves depressive symptoms in schizophrenia: a double-blind randomized placebo-controlled study with an open-label extension phase
    Terevnikov, Viacheslav
    Stenberg, Jan-Henry
    Tiihonen, Jari
    Joffe, Marina
    Burkin, Mark
    Tchoukhine, Evgueni
    Joffe, Grigori
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2011, 26 (03) : 188 - 193
  • [8] Efficacy and Safety of Pregabalin in Japanese Patients with Fibromyalgia: A Randomized, Double-Blind, Multicenter, Placebo-Controlled Phase III Trial and Open-Label Extension Study
    Ohta, Hiroyoshi
    Ohkura, Masayuki
    Suzuki, Makoto
    Oka, Hiroshi
    Usui, Chie
    Nishioka, Kusuki
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S792 - S792
  • [9] GLANCE Results of a phase 2, randomized, double-blind, placebo-controlled study
    Goodman, A. D.
    Rossman, H.
    Bar-Or, A.
    Miller, A.
    Miller, D. H.
    Schmierer, K.
    Lublin, F.
    Khan, O.
    Bormann, N. M.
    Yang, M.
    Panzara, M. A.
    Sandrock, A. W.
    NEUROLOGY, 2009, 72 (09) : 806 - 812
  • [10] EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 2-YEAR RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WITH OPEN-LABEL EXTENSION
    van der Heijde, Desiree
    Deodhar, Atul
    Maksymowych, Walter P.
    Sieper, Joachim
    van den Bosch, Filip
    Kim, Tae-Hwan
    Kishimoto, Mitsumasa
    Ostor, Andrew
    Combe, Bernard
    Sui, Yunxia
    Duan, Yuanyuan
    Chu, Alvina D.
    Song, In-Ho
    INTERNAL MEDICINE JOURNAL, 2022, 52 : 26 - 26
12345